A phase i study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 599-604

  Hasegawa, Yoshikazu ^b   Okamoto, Isamu ^a   Takezawa, Ken ^a   Miyazaki, Masaaki ^a   Tsurutani, Junji ^a   Yonesaka, Kimio ^a   Morinaga, Ryotaroh ^a   Tsuya, Asuka ^a   Terashima, Masaaki ^a   Kudoh, Toshihiro ^a   Azuma, Koichi ^a   Kurata, Takayasu ^a   Nishikawa, Tatsuyuki ^a   Fukuoka, Masahiro ^a   Nishimura, Yasumasa ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

Chemoradiation; Elderly; Locally advanced; Non small cell lung cancer; S 1

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RECOMMENDED DRUG DOSE; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; OXONIC ACID; TEGAFUR;

EID: 84879104597     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9833-7     Document Type: Article

References (19)

1. Blackstock AW, Govindan R (2007) Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 25:4146-4152
2. Movsas B, Scott C, Sause W, et al. (1999) The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (nsclc): a quality-adjusted survival analysis of radiation therapy oncology group (rtog) chemoradiation studies. Int J Radiat Oncol Biol Phys 45:1143-1149
3. Atagi S, Kawahara M, Tamura T, et al. (2005) Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase iii trial of the japan clinical oncology group (jcog9812). Jpn J Clin Oncol 35:195-201
4. Davidoff AJ, Gardner JF, Seal B, et al. (2011) Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 6:934-941
5. Okamoto I, Fukuoka M (2009) S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 10:290-294
6. Kawahara M, Furuse K, Segawa Y, et al. (2001) Phase ii study of s-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85:939-943
7. Zeng L, Ou G, Itasaka S, et al. (2008) Ts-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99:2327-2335
8. Fukushima M, Sakamoto K, Sakata M, et al. (2010) Gimeracil, a component of s-1, may enhance the antitumor activity of x-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 24:1307-1313
9. Ichinose Y, Seto T, Sasaki T, et al. (2011) S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: A multi-institutional phase ii trial (west japan thoracic oncology group 3706). J Thorac Oncol 6:2069-2075
10. Ohyanagi F, Yamamoto N, Horiike A, et al. (2009) Phase ii trial of s-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101:225-231
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92:205-216
12. Boku N, Yamamoto S, Fukuda H, et al. (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus s-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-1069
13. Graham MV, Purdy JA, Emami B, et al. (1999) Clinical dose-volume histogram analysis for pneumonitis after 3d treatment for non-small cell lung cancer (nsclc). Int J Radiat Oncol Biol Phys 45:323-329
14. Rodrigues G, Lock M, D'Souza D, et al. (2004) Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer - a systematic review. Radiother Oncol 71:127-138
15. Kong FM, Hayman JA, Griffith KA, et al. (2006) Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (nsclc): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65:1075-1086
16. Schild SE, Stella PJ, Geyer SM, et al. (2003) The outcome of combined-modality therapy for stage iii non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201-3206
17. Tsukuda M, Kida A, Fujii M, et al. (2005) Randomized scheduling feasibility study of s-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93:884-889
18. Takigawa N, Kiura K, Hotta K, et al. (2011) A phase i study of s-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. Lung Cancer 71:60-64
19. Atagi S, Kawahara M, Yokoyama A, et al. (2011) Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer - a phase iii trial of the japan clinical oncology group (jcog0301). Eur J Cancer 47(The European Multidisciplinary Cancer Congress):273